SEC Form 10-K Summary
Filing identity: The supplied filing is for GBS Inc., not Intelligent Bio Solutions Inc. It reports the fiscal year ended June 30, 2022, with comparative fiscal 2021 results. The requested “2021 Q4” period does not match the filing period.
Business Context and Reporting Period
GBS is an emerging-growth biosensor diagnostic technology company developing a non-invasive saliva-based glucose monitoring system consisting of a disposable Saliva Glucose Biosensor and related software and digital information system. The company also develops SARS-CoV-2 and other diagnostic applications using its licensed biosensor platform.
- Primary commercial focus is the Asia-Pacific region, with potential North American activities and worldwide SARS-CoV-2 applications.
- The Saliva Glucose Test had not received regulatory approval or been commercially launched in any jurisdiction as of the filing.
- The company had 12 full-time employees and relied on contractors, consultants, research institutions and third-party manufacturers.
Financial Performance and Position
| Metric | FY2022 | FY2021 | Change |
|---|---|---|---|
| Government support income | $437,146 | $1,980,484 | Down $1,543,338 |
| Total operating expenses | $8,774,022 | $7,553,966 | Up $1,220,056 |
| General and administrative expense | $4,920,103 | $3,359,065 | Up $1,561,038 |
| Development and regulatory expense | $3,853,919 | $3,835,703 | Up $18,216 |
| Loss from operations | $(8,336,876) | $(5,573,482) | Loss increased |
| Net loss attributable to GBS | $(8,306,051) | $(7,037,286) | Loss increased $1,268,765 |
| Basic and diluted loss per share | $(0.57) | $(0.68) | Improved per share due to higher share count |
| Cash and cash equivalents | $8,238,301 | $12,573,685 | Down $4,335,384 |
| Working capital | $6,204,989 | Not clearly provided in the filing text | Not clearly determinable |
| Total assets | $12,352,173 | $21,859,369 | Down $9,507,196 |
| Total liabilities | $5,806,402 | $6,852,748 | Down $1,046,346 |
| Shareholders’ equity | $6,545,771 | $15,006,621 | Down $8,460,850 |
The filing states that the company generated no product revenue to date. Reported income consisted primarily of government support and research and development-related incentives. Accordingly, meaningful operating margins and revenue-based profitability metrics are not applicable. Based on total government support income and operating expenses, the implied operating margin was approximately negative 1,909% in FY2022 versus approximately negative 382% in FY2021.
Net cash used in operating activities was $3,358,034 in FY2022, compared with $11,296,477 in FY2021. Investing cash outflows were $880,221, including a $500,000 unsecured note receivable issued to Intelligent Fingerprinting Limited and $380,221 for construction in progress. There were no financing cash inflows in FY2022; FY2021 included substantial IPO and other equity proceeds.
The company reported no material conventional debt outstanding at June 30, 2022. Liabilities primarily consisted of accounts payable and accrued expenses, deferred government grant income and employee benefit liabilities.
Material Changes Versus the Prior Comparable Period
- Government support income declined sharply after COVID-19-related support ended and prior-period support was not repeated.
- General and administrative expense increased substantially as post-IPO operating activities, headcount and consulting activity expanded.
- Development and regulatory expense was broadly stable, but included a $2.6 million non-cash charge related to a prior research and development contribution.
- Interest expense fell from $1.1 million to $7,539 because convertible notes had converted into common stock in connection with the IPO.
- Operating cash burn improved year over year, but cash declined by $4.3 million because the company continued funding development, construction and strategic activities.
- Common shares outstanding increased from 13,582,122 at June 30, 2021 to 14,889,904 at June 30, 2022, primarily due to warrant exercises and conversion of preferred stock.
- The company identified a material weakness in internal control over financial reporting and concluded that disclosure controls and procedures were not effective at June 30, 2022.
Guidance, Outlook, Risks and Unusual Items
- Management did not provide quantified revenue or earnings guidance and stated that it does not expect near-term revenue until product development, regulatory approvals and commercialization are completed.
- Management expects construction of a pilot manufacturing facility at the University of Newcastle to commence before the end of calendar 2022. The company had received approval for up to $4.7 million of Australian government grant funding subject to milestones.
- A clinical study involving 40 adults with type 2 diabetes and approximately 1,400 blood and oral-fluid samples was completed; analysis was expected to be announced in September 2022. The filing does not provide final study results.
- On June 16, 2022, GBS provided Intelligent Fingerprinting Limited with a $500,000 unsecured bridge loan while evaluating a potential acquisition. Repayment was due upon specified events, including termination of exclusivity or December 31, 2022. Completion of any acquisition was uncertain.
- The company has an option to acquire exclusive North American glucose-field licensing rights for $5 million, subject to the terms of the option agreement.
- The auditor included a going-concern explanatory paragraph. Management stated that $8.23 million of cash may be insufficient to fund the operating plan for at least 12 months, particularly if the proposed acquisition proceeds, creating substantial doubt about continuing as a going concern.
- Additional equity or debt financing may be required and could be unavailable, costly or dilutive. Management was evaluating private-placement and public-equity financing.
- GBS had not obtained regulatory approval in any jurisdiction. Key risks include clinical and regulatory delays, manufacturing scale-up, reliance on distributors and suppliers, competitive pressure, reimbursement uncertainty, cybersecurity and patient-data privacy obligations.
- The core technology is licensed from Life Science Biosensor Diagnostics Pty Ltd. The licensor entered external administration and proposed an equity recapitalization, creating uncertainty regarding control of the licensed intellectual property and the company’s continued ability to use it.
- Nasdaq notified the company that its share price had remained below the $1.00 minimum bid requirement for 30 consecutive business days. The company sought an additional compliance period, but no further extension had been granted as of the filing date.
Most Important Facts for Investors to Verify
- Confirm the correct issuer and period: the supplied document is GBS Inc.’s FY2022 Form 10-K, not an Intelligent Bio Solutions Inc. filing or a 2021 fourth-quarter report.
- Verify the company’s current cash balance, operating burn rate and financing completed after June 30, 2022.
- Assess whether the going-concern uncertainty has been resolved and whether additional financing caused material dilution.
- Verify regulatory status, clinical-study results and the timetable for commercialization of the Saliva Glucose Test.
- Confirm the status and repayment of the $500,000 Intelligent Fingerprinting bridge loan and whether any acquisition was completed.
- Review the status of Life Science Biosensor Diagnostics’ external administration and the company’s continuing license rights.
- Monitor Nasdaq listing compliance and any reverse stock split or other actions taken to maintain the listing.
- Evaluate remediation of the disclosed material weakness in internal control over financial reporting.